5-Methyl-3-propyl-1,2,4-triazol | 51824-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Methyl-3-propyl-1,2,4-triazol
• 英文别名: 3-methyl-5-propyl-4H-[1,2,4]triazole；3-methyl-5-propyl-1H-1,2,4-triazole；5-methyl-3-propyl-1H-1,2,4-triazole
• CAS: 51824-92-1
• 化学式: C₆H₁₁N₃
• mdl: MFCD11215024
• 分子量: 125.173
• InChiKey: PLSXIQIFBAFZGG-UHFFFAOYSA-N

物化性质

• 沸点：
  273.8±9.0 °C(Predicted)
• 密度：
  1.044±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE DÉSOXYURIDINE TRIPHOSPHATASE LIÉS À UN CYCLE AZOTE
  申请人：CV6 THERAPEUTICS NI LTD

  公开号：WO2018098208A1

  公开（公告）日：2018-05-31

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

  本文件提供了dUTPase抑制剂，包含此类化合物的组合物以及使用此类化合物和组合物的方法。
• AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS
  申请人：Bignan Gilles

  公开号：US20110200587A1

  公开（公告）日：2011-08-18

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物，并用于治疗包括但不限于强直性脊柱炎、动脉粥样硬化、关节炎（如类风湿关节炎、感染性关节炎、儿童关节炎、银屑病性关节炎、反应性关节炎）、与骨相关的疾病（包括与骨形成有关的疾病）、乳腺癌（包括对抗雌激素治疗无效的癌症）、心血管疾病、软骨相关疾病（如软骨损伤/丧失、软骨退化以及与软骨形成有关的疾病）、软骨发育不全、软骨肉瘤、慢性背部损伤、慢性支气管炎、慢性炎症性气道疾病、慢性阻塞性肺病、糖尿病、能量稳态紊乱、痛风、假性痛风、脂质紊乱、代谢综合征、多发性骨髓瘤、肥胖、骨关节炎、遗传性骨发育不全、骨溶解性骨转移、软骨软化症、骨质疏松症、帕金森病、牙周病、多肌痛风、Reiter综合征、重复性应激损伤、高血糖、血糖水平升高和胰岛素抵抗等疾病的方法。
• [EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE-1
  申请人：PHARMACYCLICS LLC

  公开号：WO2017205766A1

  公开（公告）日：2017-11-30

  Disclosed herein are inhibitors of IRAK protein kinase of formula (I). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了一种化学式（I）的IRAK蛋白激酶抑制剂。还披露了包含这些化合物的药物组合物。描述了使用这些IRAK抑制剂的方法，单独或与其他治疗剂合并使用，用于治疗自身免疫性疾病或症状、异源免疫性疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• [EN] INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE<br/>[FR] INHIBITEURS DE LA KINASE ASSOCIÉE AU RÉCEPTEUR DE L'INTERLEUKINE 1
  申请人：PHARMACYCLICS LLC

  公开号：WO2017205762A1

  公开（公告）日：2017-11-30

  Disclosed herein are inhibitors of IRAK protein kinase. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文揭示了抑制IRAK蛋白激酶的抑制剂。还揭示了包括这些化合物的制药组合物。描述了使用IRAK抑制剂的方法，单独或与其他治疗剂联合使用，用于治疗自身免疫性疾病或病况、异种免疫性疾病或病况、癌症（包括淋巴瘤）和炎症性疾病或病况。
• VINYLOGOUS THIOESTER COMPOUNDS AND METHODS OF USE
  申请人：THE TRUSTEES OF DARTMOUTH COLLEGE

  公开号：US20170152262A1

  公开（公告）日：2017-06-01

  Provided herein are vinylogous thioester compounds and methods for using the compounds.

  本文提供了含烯丙基硫酯化合物及使用该化合物的方法。